Breaking News
December 19, 2018 - Researchers uncover genes that play a key role in the inactivation of X chromosomes
December 19, 2018 - The case for the federal minister of health to recall them
December 19, 2018 - Regular theatre and cinema visits keeps depression away in seniors finds study
December 19, 2018 - Personalization techniques give a new lease of life to anticancer vaccines
December 19, 2018 - Research opens door to development of drug or vaccine for late-onset Alzheimer’s
December 19, 2018 - Single workout can boost metabolism for days
December 19, 2018 - UI study leads to better understanding of signaling capacity between neurons
December 19, 2018 - Gut microbiome plays role in immune system regulation, study finds
December 19, 2018 - How MAPK translocation leads to drug resistance in melanoma
December 19, 2018 - Increasing prevalence of antibiotic resistance in the U.S. linked with occasional use
December 19, 2018 - Mind-body exercises may improve cognition in older adults
December 19, 2018 - Hepatitis C drug can eliminate chikungunya, yellow fever virus
December 19, 2018 - Separating male and female mice changes the way they smell, shows study
December 19, 2018 - FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
December 19, 2018 - Mediterranean Diet for Osteoarthritis | About OA
December 19, 2018 - Successful bladder repair using silk fibroid scaffolds
December 19, 2018 - Quidel receives CE mark to use Sofia 2 Lyme+ Fluorescent Immunoassay with Sofia 2 analyzer
December 19, 2018 - Horizon Discovery partners with C4XD to validate novel synthetic lethal oncology targets
December 19, 2018 - Research suggests a promising therapeutic target to treat or prevent metabolic disorders
December 19, 2018 - Split liver transplants could save children on wait list finds study
December 19, 2018 - Michigan-based food manufacturer ordered to discontinue operations after recurrent food safety violations
December 19, 2018 - HPV discovery could lead to new treatments for cervical cancer
December 19, 2018 - Real-time neurofeedback controls Parkinson’s brainwaves
December 19, 2018 - Incorrect prescribing warnings in electronic prescribing systems
December 19, 2018 - New $1.6 million NIH grant supports study on a gene vital to circadian rhythms
December 19, 2018 - Racial Disparities Seen Among Teens Undergoing Flu Vaccination
December 19, 2018 - To resolve inflammation, location matters
December 19, 2018 - Dancing could help older women to perform their daily tasks
December 19, 2018 - Research identifies new therapeutic target for cancer treatment and tissue regeneration
December 19, 2018 - Energy costs, social isolation contribute to health risk of older adults in extreme weather
December 19, 2018 - Potential combination therapy against rare disease of the bone marrow could improve treatment
December 19, 2018 - Researchers aim to improve cognition, reverse weight gain in schizophrenia
December 19, 2018 - UC San Diego Health offers new DRG stimulation device for phantom limb pain
December 19, 2018 - Study examines relationship between growth restriction and risk of childhood mortality
December 19, 2018 - New study provides insights on increased risk of suicide in young patients visiting ED
December 19, 2018 - AHA: Thyroid Problems Linked to Worsening Heart Failure
December 19, 2018 - World-first coeliac disease vaccine enters Phase 2 trials
December 19, 2018 - RNA sequencing offers novel insights into the microbiome
December 19, 2018 - A promising, effective vaccine for common respiratory disease
December 19, 2018 - Protein may slow progression of emphysema, study finds
December 19, 2018 - Studying atrial fibrillation — and exploring new frontiers in precision health
December 19, 2018 - A New Way To Get College Students Through A Psychiatric Crisis — And Back To School
December 19, 2018 - Optum, UnitedHealthcare take action to help people affected by North Carolina winter storms
December 18, 2018 - Weight change in middle-aged, elderly Chinese Singaporeans related to increased risk of death
December 18, 2018 - Immune cells sacrifice themselves to protect us from invading bacteria
December 18, 2018 - Watching brain cells fire, with a twist of gravitational waves
December 18, 2018 - 2018 in Review
December 18, 2018 - Getting the Most Out of the CLARITY Technique
December 18, 2018 - NVF shoes provide a viable option for track and road racing
December 18, 2018 - CRISPR may restore effectiveness of chemotherapies used to treat lung cancer
December 18, 2018 - New app accurately measures and charts progression of skin wounds
December 18, 2018 - Persistent Discrimination ID’d Among Physician Mothers
December 18, 2018 - Cellphone technology developed to detect HIV
December 18, 2018 - A Stanford doctor hits the field with the 49ers — as their airway management physician
December 18, 2018 - The Rise of Anxiety Baking
December 18, 2018 - Just one night of sleep deprivation increases the urge to eat
December 18, 2018 - Study reveals mechanism behind failed remyelination in MS
December 18, 2018 - New genetic testing method increases the precision of biomarker analysis
December 18, 2018 - Simple technique to effectively treat underdiagnosed cause of debilitating chest pain
December 18, 2018 - Barbershop-based medical intervention can successfully lower blood pressure, new data shows
December 18, 2018 - Food labels have caused changes in consumers’ intake and industry’s use of key additives
December 18, 2018 - Sickest children could benefit from split liver transplants
December 18, 2018 - Scientists create patient-specific model to identify most effective treatment for appendix cancer
December 18, 2018 - ‘Little Foot’ endocast reveals a small brain combining ape-like and human-like features
December 18, 2018 - New therapy for childhood blindness shows ‘very promising’ results
December 18, 2018 - Researchers discover promising new compound against Buruli ulcer
December 18, 2018 - Study finds significant use of traditional, complementary and alternative medicines in Sub-Saharan Africa
December 18, 2018 - California Farm Implicated in Outbreak of E. coli Tied to Romaine Lettuce
December 18, 2018 - Mobile health has power to transform HIV/AIDS nursing
December 18, 2018 - Celiac Vaccine in Clinical Trials at Columbia
December 18, 2018 - Research into mental health first aid prompts practical guidance and resources for workplace
December 18, 2018 - Researcher conducts study to investigate peripheral blood markers of Alzheimer’s disease
December 18, 2018 - Researchers identify link between mucus in the small airways and pulmonary fibrosis
December 18, 2018 - EU Commission’s Health Policy Platform to host EKHA program on transplantation
December 18, 2018 - Survivors of childhood Hodgkin lymphoma have high risk of developing solid tumors
December 18, 2018 - Small changes to cafeteria design can get kids to eat healthier, new assessment tool finds
December 18, 2018 - From Machines to Cyclic Compounds
December 18, 2018 - New study reveals best assessment tools to establish delirium severity
December 18, 2018 - Rice University scientists develop synthetic protein switches to control electron flow
December 18, 2018 - Home-based pulmonary function monitoring for teens with Duchenne muscular dystrophy
FDA Approves Accelerated 7-Day Vaccine Dosing Schedule for Ixiaro

FDA Approves Accelerated 7-Day Vaccine Dosing Schedule for Ixiaro

image_pdfDownload PDFimage_print

GAITHERSBURG, Md.–(BUSINESS WIRE) October 05, 2018 –Valneva USA, the U.S. subsidiary of global vaccine biotech company Valneva SE, today announced U.S. Food and Drug Administration (FDA) approval of an accelerated dosing regimen for Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed), the only vaccine approved in the United States indicated for protection against disease caused by Japanese encephalitis (JE) virus.

Japanese encephalitis – a rare but serious disease and the most common form of vaccine-preventable encephalitis and viral-induced neurologic disability in Asia – is endemic to 24 countries in Asia and parts of the Western Pacific.i For effective protection from JE virus, adults aged 18 to 65 years may now receive two separate doses of Ixiaro seven days apart. Previously, the time between doses for this age group was 28 days. The standard 28-day schedule still applies to children two months to 17 years and adults 66 years and older; adults aged 18 to 65 years may also follow this schedule. The accelerated and the standard dosing schedules must be completed at least seven days before travel to endemic areas.

“The FDA approval of this accelerated 7-day dosing schedule is a positive step toward protecting more people from JE,” said Charles Daily, Valneva General Manager, U.S. “For travelers who do seek protection with a vaccine prior to travel, oftentimes they are not aware of the dosing schedule and therefore have not visited their doctor soon enough to allow for two doses. Eliminating this time barrier will make it easier for patients to plan for their travel health needs and to better protect themselves.”

A recent survey found that 72 percent of U.S. adults who traveled to Asia for 10 or more days reported visiting at least one area, or participating in an activity, that put them at increased risk for exposure to JEii virus and, based on guidelinesiii, should consider a vaccine along with other protective measures. However, the same survey found that more than one-third began preparing for travel less than a month before departure.

“I encourage anyone planning international travel to visit a travel health practitioner well in advance of their anticipated departure date to learn about preventative measures for travel-related diseases,” said Dr. Scott Morcott, family physician and Medical Director of Passport Health Chicago. “For those whose travel plans change unexpectedly, this shorter vaccine dosing regimen may help to protect them in less time.”

According to the World Health Organization, JE is endemic to 24 countries across Asia and parts of the western Pacific. While most people infected with JE virus – which is transmitted by mosquitoes – are asymptomatic or experience only mild symptomsiv, it can be fatal or cause long-term serious complications. There is no specific treatment for JE, and the Centers for Disease Control and Prevention (CDC) recommends that, in addition to personal protective measures, travelers who spend 30 days or more in a JE-endemic region be vaccinated prior to arrival. In addition, shorter-term travelers should consider vaccination if their activities or location put them at risk for a mosquito bite.

About the Survey

The survey of 776 adults (18+) from across the United States was conducted in May-June 2018 to better understand the awareness and knowledge of health risks related to international travel. Of those queried, 514 participants had traveled to Asia for 10-29 days within the past 24 months, and 262 participants had traveled for 30 or more days.

About Ixiaro

Valneva is the manufacturer of Ixiaro, a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals two months of age and older.

For adults aged 18 to 65, the vaccine is given in two doses, seven days apart (accelerated schedule) or 28 days apart (standard schedule), and vaccination should be completed seven days prior to potential exposure to JE virus.

For pediatric (two months to <18 years) and older adult (66+ years) travelers, the vaccine is given in two doses, 28 days apart (standard schedule), and vaccination should be completed seven days prior to potential exposure to JE virus.

About Japanese Encephalitis

JE is a deadly infectious disease that is endemic to 24 countries across Asia, Southeast Asia, and the western Pacific. About 68,000 cases of JE are estimated to occur each year, although the actual number of cases is likely much higher due to underreporting in rural areas. JE is fatal in up to 30 percent of those who show symptoms, and up to half of survivors continue to have neurologic, cognitive, and psychiatric impairment. In 2005, JE killed more than 1,200 children in only one month during an epidemic outbreak in Uttar Pradesh, India, and Nepal.

According to the CDCv, the risk of JE is low for most travelers to Asia but can vary based on various factors, such as where a person spends time, when and for how long they are traveling and their activities. Travelers staying one month or longer (for example, military members and their families, study abroad students, or employees with extended work assignments) in parts of Asia where the JE virus is found are recommended for vaccination. Vaccination should be considered for travelers who have an increased risk of being exposed to mosquitoes carrying JE virus if they spend substantial time outdoors or in rural areas, especially at night; participate in extensive active outdoor activities such as camping, hiking, biking, fishing, or hunting, or sleep in accommodations without mosquito nets; or whose plans are uncertain or may change. JE vaccine is not recommended for short-term travel restricted to urban areas or outside of the JE virus transmission season.

For more information about JE and Ixiaro, or for the full prescribing information, visit www.PreventJE.com.

About Valneva USA, Inc.

Valneva USA, Inc. is a subsidiary of Valneva SE, a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines.

Valneva USA is focused on the marketing and distribution of Valneva’s vaccines, including Ixiaro, in the United States. For more information, follow Valneva on Twitter @ValnevaUSA or on Facebook.

i World Health Organization. Japanese encephalitis Fact sheet no.386. December 2015. http://www.who.int/mediacentre/factsheets/fs386/en. Accessed October 1, 2018.

ii Data on file.

iii Centers for Disease Control and Prevention. Japanese encephalitis. Updated August 2015. https://www.cdc.gov/japaneseencephalitis/. Accessed October 1, 2018.

iv World Health Organization. Japanese encephalitis Fact sheet no.386. December 2015. http://www.who.int/mediacentre/factsheets/fs386/en. October 1, 2018.

v Prevention, C. (2018). Japanese Encephalitis – Chapter 3 – 2018 Yellow Book | Travelers’ Health | CDC. [online] wwwnc.cdc.gov. Available at: https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/japanese-encephalitis [Accessed October 1, 2018].

Source: Valneva USA

Posted: October 2018

Related Articles:

Ixiaro (Japanese Encephalitis Virus Vaccine, Inactivated, Adsorbed) FDA Approval History

Tagged with:

About author

Related Articles